Sprint Precision Technologies
688605
Jiangsu Jingxue Insulation Technology
301010
Global Infotech
300465
Sunfly Intelligent Technology
300423
Hydsoft Technology
301316
CN Stock MarketDetailed Quotes
002332 Zhejiang Xianju Pharmaceutical
- 11.75
- +0.12+1.03%
Trading Dec 12 13:23 CST
11.62BMarket Cap18.71P/E (TTM)
11.83High11.55Low156.85KlotVolume11.65Open11.63Pre Close183.70MTurnover1.59%Turnover Ratio20.65P/E (Static)989.20MShares14.8052wk High1.93P/B11.57BFloat Cap8.1452wk Low12.79Limit Up984.57MShs Float18.64Historical High10.47Limit Down2.41%Amplitude2.18Historical Low0.30Dividend TTM11.71Avg Price76.25KlotAsk2.55%Div YieldTTM100Lot Size77.96KlotBid
Zhejiang Xianju Pharmaceutical Key Stats
All
YOY
| (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q9)Sep 30, 2022 | (Q6)Jun 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | -0.01%3.24B | 0.93%2.14B | 8.42%1.04B | -5.85%4.12B | -6.24%3.24B | -4.93%2.12B | -8.75%957.29M | 0.52%4.38B | 4.09%3.45B | 3.96%2.23B |
| Operating revenue | -0.01%3.24B | 0.93%2.14B | 8.42%1.04B | -5.85%4.12B | -6.24%3.24B | -4.93%2.12B | -8.75%957.29M | 0.52%4.38B | 4.09%3.45B | 3.96%2.23B |
| Other operating revenue | ---- | -14.09%12.17M | ---- | 104.30%43.96M | ---- | 11.33%14.17M | ---- | -4.18%21.52M | ---- | 23.78%12.73M |
| Total operating cost | -2.84%2.61B | -0.70%1.73B | 9.84%872.35M | -4.22%3.49B | -5.18%2.68B | -5.21%1.74B | -11.65%794.2M | -0.72%3.64B | 2.69%2.83B | 2.65%1.84B |
| Operating cost | -6.95%1.47B | -5.67%965.4M | 2.14%465.93M | 6.02%1.94B | 7.38%1.58B | 9.81%1.02B | 3.61%456.18M | 0.26%1.83B | 8.36%1.47B | 4.16%931.93M |
| Operating tax surcharges | -3.76%24.01M | -2.09%16.62M | 3.94%5.59M | -4.35%36.87M | -10.60%24.95M | -9.93%16.97M | -19.14%5.38M | -0.49%38.54M | -4.72%27.9M | 3.00%18.84M |
| Operating expense | -0.09%726.21M | 6.28%488.13M | 15.65%255.8M | -21.60%989.98M | -27.39%726.84M | -29.63%459.3M | -30.09%221.19M | -1.33%1.26B | 7.14%1B | 12.83%652.7M |
| Administration expense | -2.77%226.13M | 0.04%158.81M | 15.19%82.39M | 4.31%281.23M | 16.77%232.56M | 10.19%158.75M | -1.19%71.53M | -3.77%269.6M | -23.48%199.17M | -21.02%144.07M |
| Financial expense | -19.01%-23.33M | -152.77%-23.6M | -315.93%-5.86M | 16.45%-22.32M | -0.07%-19.6M | -45.10%-9.33M | -123.96%-1.41M | -40,784.61%-26.71M | -209.62%-19.59M | -136.68%-6.43M |
| -Interest expense (Financial expense) | -46.08%1.39M | -46.37%937.73K | -31.17%596.19K | -46.47%3.37M | -64.95%2.57M | -71.38%1.75M | -75.00%866.15K | -72.78%6.29M | -55.48%7.34M | -53.25%6.11M |
| -Interest Income (Financial expense) | 14.09%-24.44M | -2.61%-19.08M | -2.08%-7.31M | -40.79%-38.28M | -215.12%-28.45M | -203.06%-18.59M | -144.46%-7.16M | -86.12%-27.19M | 12.42%-9.03M | 24.72%-6.14M |
| Research and development | 32.46%184.73M | 33.79%124.96M | 65.73%68.51M | -2.16%261M | -7.54%139.46M | -3.79%93.4M | -27.95%41.34M | 9.61%266.77M | -3.87%150.82M | -2.18%97.07M |
| Credit Impairment Loss | -13.44%-7.7M | 54.29%-5.22M | 31.93%-5.99M | 154.33%5.04M | 49.88%-6.78M | 7.96%-11.43M | -47.36%-8.8M | -178.97%-9.27M | -72.83%-13.54M | -76.97%-12.42M |
| Asset Impairment Loss | 14.27%-23.57M | 12.00%-24.22M | ---- | 11.21%-28.56M | -69.24%-27.49M | -48.01%-27.52M | ---- | -57.54%-32.16M | 28.74%-16.25M | 18.56%-18.59M |
| Other net revenue | 100.65%64.77K | 108.26%1.83M | 291.21%18.41M | -90.94%12.92M | -128.90%-9.92M | -197.43%-22.13M | -364.16%-9.63M | 99.70%142.54M | 945.90%34.31M | 262.14%22.71M |
| Fair value change income | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --3.87M | --2.32M |
| Invest income | 11.97%12.75M | 107.22%17.9M | 1,677.20%18.68M | -118.18%-8.97M | -70.86%11.39M | -75.58%8.64M | -133.60%-1.18M | 72.67%49.35M | 213.96%39.08M | 312.47%35.36M |
| -Including: Investment income associates | -108.17%-930.85K | -51.21%4.21M | 521.81%5M | -105.35%-7.95M | 112.29%11.39M | 108.48%8.64M | -133.60%-1.18M | -143.32%-3.87M | -38.36%5.36M | -43.05%4.14M |
| Asset deal income | 57.18%-730.69K | 103.54%61.58K | 104.33%64.29K | -101.61%-1.48M | -3,866.88%-1.71M | -3,936.07%-1.74M | ---1.48M | 531.50%91.62M | -99.18%45.3K | 231.85%45.35K |
| Other revenue | 31.55%19.31M | 34.16%13.31M | 206.70%5.66M | 9.05%46.89M | -30.44%14.68M | -37.99%9.92M | -69.73%1.84M | 18.40%43M | 145.56%21.1M | 119.18%16M |
| Operating profit | 15.71%630.73M | 15.79%409.36M | 19.89%183.98M | -26.42%646.46M | -17.19%545.1M | -14.31%353.52M | -0.16%153.46M | 15.81%878.6M | 17.92%658.24M | 21.88%412.54M |
| Add:Non operating Income | -51.30%1.73M | -22.41%1.7M | 9.58%1.23M | 191.35%4.32M | -36.69%3.55M | 3,381.62%2.19M | 375.81%1.12M | 112.34%1.48M | 57.09%5.61M | -88.88%63.04K |
| Less:Non operating expense | -11.53%4.75M | -5.26%3.94M | 243.30%3.08M | 11.10%9.1M | -43.40%5.36M | -50.46%4.16M | -83.90%896.75K | -72.23%8.19M | 5.71%9.48M | 100.51%8.39M |
| Total profit | 15.54%627.71M | 15.80%407.12M | 18.51%182.13M | -26.40%641.68M | -16.97%543.29M | -13.03%351.56M | 3.58%153.68M | 19.46%871.89M | 18.37%654.37M | 20.71%404.22M |
| Less:Income tax cost | 19.17%85.01M | 17.50%59.45M | 5.05%25.61M | -36.09%79.56M | -41.35%71.34M | -37.19%50.59M | -7.18%24.38M | 14.63%124.49M | 32.52%121.63M | 34.49%80.56M |
| Net profit | 14.99%542.7M | 15.52%347.68M | 21.05%156.52M | -24.79%562.12M | -11.41%471.95M | -7.01%300.97M | 5.90%129.3M | 20.30%747.4M | 15.55%532.73M | 17.70%323.66M |
| Net profit from continuing operation | 14.99%542.7M | 15.52%347.68M | 21.05%156.52M | -24.79%562.12M | -11.41%471.95M | -7.01%300.97M | 5.90%129.3M | 20.30%747.4M | 15.55%532.73M | 17.70%323.66M |
| Less:Minority Profit | 3,475.78%12.52M | 1,044.14%7.95M | 241.42%5.39M | 52.08%-965.01K | -90.05%350.04K | 88.67%-842.4K | 32.11%-3.81M | -204.03%-2.01M | 93.66%3.52M | -893.90%-7.43M |
| Net profit of parent company owners | 12.42%530.18M | 12.56%339.72M | 13.53%151.12M | -24.86%563.08M | -10.89%471.6M | -8.84%301.81M | 4.23%133.11M | 21.00%749.41M | 15.24%529.21M | 20.82%331.09M |
| Earning per share | ||||||||||
| Basic earning per share | 12.44%0.536 | 9.68%0.34 | 15.38%0.15 | -24.76%0.57 | -10.90%0.4767 | -6.06%0.31 | 0.00%0.13 | 21.00%0.7576 | 15.25%0.535 | 17.86%0.33 |
| Diluted earning per share | 12.44%0.536 | 9.68%0.34 | 15.38%0.15 | -24.76%0.57 | -10.90%0.4767 | -6.06%0.31 | 0.00%0.13 | 21.00%0.7576 | 15.25%0.535 | 17.86%0.33 |
| Other composite income | -121.30%-5.4M | -146.31%-32.59M | -308.97%-30.17M | 106.59%44.87M | 205.70%25.34M | 406.28%70.36M | 206.96%14.44M | 125.72%21.72M | 32.32%-23.97M | -8.79%-22.97M |
| Other composite income of parent company owners | -121.30%-5.4M | -146.31%-32.59M | -308.97%-30.17M | 106.59%44.87M | 205.70%25.34M | 406.28%70.36M | 206.96%14.44M | 125.72%21.72M | 32.32%-23.97M | -8.79%-22.97M |
| Total composite income | 8.05%537.3M | -15.14%315.09M | -12.10%126.34M | -21.08%606.99M | -2.26%497.29M | 23.49%371.32M | 32.36%143.74M | 43.27%769.12M | 19.53%508.76M | 18.44%300.69M |
| Total composite income of parent company owners | 5.60%524.78M | -17.47%307.14M | -18.03%120.95M | -21.16%607.95M | -1.64%496.94M | 20.79%372.17M | 29.19%147.55M | 44.17%771.13M | 19.21%505.24M | 21.82%308.12M |
| Total composite income of minority owners | 3,475.78%12.52M | 1,044.14%7.95M | 241.42%5.39M | 52.08%-965.01K | -90.05%350.04K | 88.67%-842.4K | 32.11%-3.81M | -204.03%-2.01M | 93.66%3.52M | -893.90%-7.43M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- |
| Auditor | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianjian Certified Public Accountants (Special General Partnership) | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
